Maxx Chatsko Archives - 7investing 7investing
Stock Tips Mobile Menu Dropdown Icon

Posts by Maxx Chatsko


Maxx’s Top Stock for May 2022

May 1, 2022

7investing Lead Advisor Maxx Chatsko's top stock to buy in May 2022 serves as the linchpin of for biology-driven enterprises.


Maxx’s Top Stock for March 2022

Mar 1, 2022

7investing Lead Advisor Maxx Chatsko's top stock to buy in March 2022 is on the cusp of ramping three high-growth brands large, underserved markets.


Interacting with Members and Refining My Frameworks

Feb 22, 2022

Speaking with members has helped me to fine-tune my research process with clearer communication in mind.

Premium Advisor Update

Will Solid-State Batteries Live Up to the Hype?

Feb 8, 2022


Maxx’s Top Stock for February 2022

Feb 1, 2022

7investing Lead Advisor Maxx Chatsko's top stock to buy in February 2022 has what might be the best technology stack and most methodical approach in molecular testing. That makes it well positioned...

Premium Advisor Update

“Very High Risk” Isn’t Very Helpful

Jan 26, 2022


Wild Prediction for 2022: CRISPR Stocks Become Mortal Again

Jan 22, 2022

Emerging therapeutic modalities built on the enzymatic tool will be subject to the traditional risk-reward calculus facing drug developers.

Premium Advisor Update

Should You Invest in Synthetic Biology Stocks?

Jan 14, 2022


5 Big Reveals from the 2022 JP Morgan Healthcare Conference

Jan 13, 2022

7investing Lead Advisors Simon Erickson and Maxx Chatsko discuss a handful of big reveals from the first few days of the 2022 JP Morgan Healthcare Conference.


Maxx’s Top Stock for January 2022

Jan 1, 2022

7investing Lead Advisor Maxx Chatsko's top stock to buy in January 2022 is developing a novel technology platform that's well-positioned to address some of the biggest challenges facing gene therapy...


Dicerna Pharmaceuticals Deep Dive: October 2021

Dec 28, 2021

For the first time ever, we are releasing an active recommendation to the general public as three-time recommendation Dicerna Pharmaceuticals was acquired by Novo Nordisk in a $3.3 billion deal.

Premium Advisor Update

Can Better Antibodies Disrupt Cell Therapy?

Dec 20, 2021


Investing in Emerging Markets with Perth Tolle

Dec 16, 2021

7investing Lead Advisors Matt Cochrane and Maxx Chatsko chat with Perth Tolle about investing in emerging markets as a global citizen who respects economic and personal freedoms.


Maxx’s Top Stock for December 2021

Dec 1, 2021

7investing Lead Advisor Maxx Chatsko's top stock to buy in December 2021 has just de-risked the entire therapeutic modality of gene therapy -- and Wall Street is entirely misunderstanding the...


Think Long Term, but Focus on Your Five-Meter Targets

Nov 21, 2021

Take care of business before getting too carried. Invest in companies that do the same.

Premium Advisor Update

I Choose Embarrassment

Nov 13, 2021


Maxx’s Top Stock for November 2021

Nov 1, 2021

7investing Lead Advisor Maxx Chatsko's top stock to buy in November 2021 is at the very beginning of an inflection point in its growth trajectory.


Navigating Inflation and Interest Rates with Your Hard-Earned Money

Oct 22, 2021

Even long-term investors should acknowledge the role that Fed policy is playing in stock valuations.


Blue-Sky Thinking in Synthetic Biology

Oct 19, 2021

What will it take for synthetic biology to live up to its promise? 7investing Lead Advisor Maxx Chatsko talks with visionary scientist Andrew Hessel about pushing the envelope of living technologies ...

Premium Advisor Update

Drug Development is Risky. Let’s Count the Ways.

Oct 14, 2021


7investing Explains: How are Medical Devices and Genetic Tests Regulated?

Oct 14, 2021

Health care investors often focus on drug products, but medical devices present unique investing opportunities, too. 7investing Lead Advisors Simon Erickson, Dana Abramovitz, and Maxx Chatsko provide...


Can Your Gene Editing Stocks Survive the End of Momentum?

Oct 8, 2021

There are both opportunities and challenges to modifying DNA for therapeutic applications, but objective information is scarce.